Approval history
The FDA approved Zepbound on November 8, 2023, for adults with obesity, or with overweight and at least one weight-related condition, used with a reduced-calorie diet and more physical activity. Tirzepatide had already been sold since 2022 as Mounjaro for type 2 diabetes.
On December 20, 2024, the FDA approved Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity. The FDA called it the first medicine approved for this condition.
Mechanism and evidence
Zepbound contains tirzepatide, which acts on two hormone receptors, GLP-1 and GIP. Both are gut hormones that affect insulin release, appetite and how fast the stomach empties.
The weight approval rests on the SURMOUNT trials. In SURMOUNT-1, people on the 15 mg dose lost 20.9% of their body weight on average after 72 weeks, compared with 3.1% on placebo. In SURMOUNT-OSA, the number of breathing pauses per hour of sleep (apnea-hypopnea index) fell by about 25 to 29 events on tirzepatide after 52 weeks, vs. about 5 events on placebo.
Forms and doses
Zepbound comes in single-dose pens, single-dose vials, multi-dose vials and multi-dose KwikPens. Doses range from 2.5 mg to 15 mg once a week. The label raises the dose in 2.5 mg steps over several months, a process known as titration.
Lilly released single-dose vials of Zepbound on August 27, 2024, to add supply during a period of high demand.
Side effects and availability
The most common side effects of Zepbound are nausea, diarrhea, vomiting, constipation and stomach pain. The label carries a boxed warning about thyroid C-cell tumors seen in rodents.
Zepbound is a prescription medicine. State-licensed pharmacies may also prepare compounded tirzepatide for an individual prescription, which is not an FDA-approved product. Our compounded tirzepatide page compares programs that offer it.
Timeline
- November 8, 2023FDA approves Zepbound for chronic weight management.
- August 27, 2024Single-dose vials released.
- December 20, 2024Approved for moderate to severe obstructive sleep apnea with obesity.
See also
References
- FDA Approves New Medication for Chronic Weight Management, FDA, November 8, 2023. fda.gov
- FDA Approves First Medication for Obstructive Sleep Apnea, FDA, December 20, 2024. fda.gov
- Jastreboff et al., NEJM 2022;387:205-216 (SURMOUNT-1). pubmed.ncbi.nlm.nih.gov
- Malhotra et al., NEJM 2024;391:1193-1205 (SURMOUNT-OSA). pubmed.ncbi.nlm.nih.gov
- Zepbound (tirzepatide) prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
- Lilly releases Zepbound single-dose vials, Eli Lilly press release, August 27, 2024
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.